Skip to main content
. 2011 Aug 1;4(4):249–257. doi: 10.1593/tlo.11136

Figure 2.

Figure 2

(A) CVX-045 (-▴-) inhibits growth of A431 xenograft at a dose of 10 mg/kg administered weekly. The reduction in tumor volume was statistically significant (P < .05, two-way ANOVA with Bonferroni correction, n = 9 per group) by day 21 when compared with the growth of vehicle-treated tumors (-■-). (B) CVX-045 (-▴-) inhibits growth of A549 xenograft at a dose of 10 mg/kg administered weekly. The reduction in tumor volume was statistically significant (P < .05, two-way ANOVA with Bonferroni correction, n = 9 per group) at day 49 when compared with the growth of vehicle-treated tumors (-■-). (C) CVX-045 treatment (10 mg/kg 1x/wk) significantly reduces (P < .05, one-way ANOVA, Newman-Keuls multiple comparison test, n = 5 per group) the viable tumor volume of A549 tumors when compared with PBS-treated tumors. (D) CVX-045 treatment (10 mg/kg 1x/wk) significantly reduces (P < .05, one-way ANOVA, Newman-Keuls multiple comparison test, n = 5 per group) the viable tumor volume of A431 tumors when compared with PBS-treated tumors. (E) CVX-045 treatment (10 mg/kg 1x/wk) significantly reduces (P < .05, one-way ANOVA, Newman-Keuls multiple comparison test, n = 5 per group) the microvessel density of A549 tumors when compared with PBS-treated tumors. (F) CVX-045 treatment (10 mg/kg 1x/wk) significantly reduces (P < .05, one-way ANOVA, Newman-Keuls multiple comparison test, n = 5 per group) the microvessel density of A431 tumors when compared with PBS-treated tumors.